Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug ...

Shares of Merck & Co. Inc. MRK inched 0.08% higher to $99.45 Tuesday, on what proved to be an all-around favorable trading ...

Merck, a leading global pharmaceutical company that produces a range of medicines, vaccines, and animal healthcare products, ...

A Fremont pharmaceutical company received an investment of approximately $50 million — about $3.56 per share — in a private ...

And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...

The weight-loss biotech Viking Therapeutics ( VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

Merck has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to treat ...

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk ...